Pharming Group shares are trading higher after the company announced the commercial launch of Joenja in Japan for adult and pediatric patients with activated PI3K delta syndrome aged 4 years and older.

Pharming Launches Joenja (Leniolisib) in Japan for APDS Patients Aged 4 and Older, Marking First Global Launch for Children 4 To 11

Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwideOrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and distribution in Japan

Canaccord Genuity Maintains Buy on Pharming, Raises Price Target to $38

Canaccord Genuity analyst Whitney Ijem maintains Pharming (NASDAQ:PHAR) with a Buy and raises the price target from $37 to $38.

Pharming shares are trading lower after the company reported Q2 financial results and lowered its FY26 sales guidance below analyst estimates.